A lot of hope – and hype – surround the immunotherapy drugs flagged to treat Alzheimer’s disease. The jury is out on their real-life benefit, while the push continues for earlier diagnosis.
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.